Dashboard
Portfolios
Watchlist
Community
Discover
Screener
Community
/
China
/
Pharmaceuticals & Biotech
/
Sichuan Kelun Pharmaceutical
002422
Sichuan Kelun Pharmaceutical
International Regulatory Hurdles And China Pricing Pressure Will Erode Margins
AN
AnalystLowTarget
Not Invested
Consensus Narrative from 7 Analysts
Published
24 Aug 25
Updated
24 Aug 25
0
Set Fair Value
0
votes
Share
AnalystLowTarget
's Fair Value
CN¥32.00
19.4% overvalued
intrinsic discount
24 Aug
CN¥38.20
1Y
17.4%
7D
1.4%
Loading
1Y
17.4%
7D
1.4%
Author's Valuation
CN¥32.0
19.4% overvalued
intrinsic discount
AnalystLowTarget Fair Value
View Valuation
Narrative
Updates
0
Valuator
Company Info
Notes
AnalystLowTarget Fair Value
CN¥32.0
19.4% overvalued
intrinsic discount
Future estimation in
3 Years
time period
Past
Future
0
25b
2014
2017
2020
2023
2025
2026
2028
Revenue CN¥25.2b
Earnings CN¥3.6b
Revenue
Profit Margin
Future PE
Revenue
% p.a.
0
Decrease
Increase
Current revenue growth rate
8.52%
Pharma revenue growth rate
0.58%
Other Inputs & Calculation
Risk Level (Discount Rate)
Our default considers factors like the company's size, volatility, profitablity and country of operation.
Risk Level (Discount Rate)
%
0
Decrease
Increase
Current discount rate
6.83%
Calculation
CN¥3.56b
Earnings '28
x
17.19x
PE Ratio '28
=
CN¥61.18b
Market Cap '28
CN¥61.18b
Market Cap '28
/
1.56b
No. shares '28
=
CN¥39.29
Share Price '28
CN¥39.29
Share Price '28
Discounted to 2025 @ 6.83% p.a.
=
CN¥32.23
Fair Value '25
